- Atherectomy and intravascular lithotripsy (IVL) Devices are increasingly vital in modern vascular and endovascular procedures due to their minimally invasive approach to treating calcified arterial blockages. These devices are essential for improving luminal gain, vessel compliance, and preparing calcified plaques for optimal stent placement or drug delivery
- The escalating demand for atherectomy and IVL devices is primarily driven by the rising global prevalence of peripheral artery disease (PAD), coronary artery disease (CAD), and the growing aging population with comorbidities such as diabetes and hypertension that increase the risk of arterial calcification
- North America dominated the atherectomy and intravascular lithotripsy (IVL) devices market with the largest revenue share of 41.6% in 2024, attributed to the high burden of cardiovascular diseases, favorable reimbursement policies, strong presence of leading medical device companies, and rapid adoption of advanced vascular intervention technologies across the U.S. and Canada
- Asia-Pacific is expected to be the fastest growing region in the atherectomy and intravascular lithotripsy (IVL) devices market during the forecast period (2025–2032), owing to increasing healthcare expenditure, improving access to cardiovascular care, and rising incidence of PAD and CAD across aging populations in countries such as China, India, and Japan
- The atherectomy devices segment dominated the atherectomy and intravascular lithotripsy (IVL) devices market, with a revenue share of 58.6% in 2024, attributed to their widespread use in treating peripheral and coronary artery diseases involving plaque and calcification. Their versatility across various lesion morphologies and compatibility with existing interventional tools have boosted adoption among interventional cardiologists and vascular surgeons
